tis patients (median age, 83 years; range, 73-86 years) died from their illness. While many patients reported temporary numbness in their extremi ties, no cases of acute flaccid paralysis were identified. Ninety-five (64%) case-patients were male. The overall median case-patient age was 47 years (range, 2-96 years). WN encephalitis patients tended to be older (median, 74 years; range, 38-96 years), but WN meningitis patients were younger (median, 38 years; range, 2-80 years). The earliest case-patient had onset of symptoms on June 18; the latest, on October 1 ( Most cases occurred among residents of western and central Minnesota (Figure 1 ), but not all of these patients became exposed to infected mosqui toes near their residences. Twentythree (16%) case-patients traveled outside of Minnesota during the entire 2 weeks (the possible incubation period for WNV disease) prior to the onset of the illness. Most of these people traveled to other Great Plains states. Another 16 (11%) case-patients traveled to other states during part of the 2-week period prior to illness onset; thus, they may have been exposed either in Minnesota or outside the state. Many of these people regularly traveled to North Dakota or South Dakota. After excluding cases in which exposure to the virus may have occurred outside of Minnesota, WNV disease incidence rates were signifi cantly higher in western and south western Minnesota than in eastern Minnesota, including in the Twin Cities Map Interpretation: Geographic variation of WNV-infected humans, horses, chickens, mosquitoes, and birds reflect, in part, population density, awareness of West Nile fever, location of farms and stables, location of mosquito traps, and total number of birds submitted for testing. . Culex tarsalis birds, but seldom feed on humans. The 4). In several parts of west central and southwestern Minnesota, Cx. tarsalis numbers and infection rates peaked just prior to the peak of human cases, in mid to late August (Figure 4) .
Predictions for 2004 and Beyond
The field ecology of WNV is extremely complex. It is difficult to predict how many people will become infected with WNV in Minnesota or in the rest of North America in 2004. The virus appears to be established throughout Minnesota; it will probably be present in the state to some extent every year. The disease risk to humans, however, will likely continue to be higher in central and western Minnesota, where Cx. tarsalis is most abundant. The risk is also likely to be highest from August through mid-September. Ultimately, the risk in any given year will be largely dependent on: 1) the weather (warm weather, with timely wet and dry conditions, enhances the production of vector mosquitoes), 2) the presence of the virus in mosquitoes and suscep tible birds that can act as reservoirs for the virus, and 3) human behavior patterns (the level of outdoor activity at dusk and dawn, when Cx. tarsalis is active, and the relative amount of personal measures taken by people to protect themselves from the vector mosquitoes).
species-, site-, and date-specific "pools") for WNV. Fifty-nine pools of mosquitoes from 9 counties tested positive for the virus. The continued...
• 3 months plus duration of symptoms for primary syphilis; • 6 months plus duration of symptoms for secondary syphilis; and • 1 year for early latent syphilis.
The preferred drug treatment for all stages of syphilis is penicillin G, but the preparations used, their dosage, and their length of treatment depend on the stage and clinical manifestations of the disease. For more specific information, consult the CDC 2002 treatment guidelines. Adults diagnosed with primary, secondary, or early latent syphilis should be treated with 
Cancer Rates Among American Indians in Minnesota
According to the 2000 Census, an estimated 3 million American Indians and Alaska Natives (AI/ANs) live in the United States, including 62,673 in Minnesota. 1 Although AI/ANs account for less than 1% of the U.S. population, they experience a disproportionate burden of many chronic diseases, especially diabetes and heart disease, as well as injuries. 2, 3 National data have indicated that AI/ANs have an overall lower cancer risk than other racial and ethnic groups. 4 However, a recent report from the Centers for Disease Control and Prevention showed large geographic variations in cancer mortality among AI/ANs and demonstrated that Northern Plains Indians have mortality rates for several common cancers that are about twice those among American Indians in the Southwest. 5 Incidence data from the Minnesota Cancer Surveillance System (MCSS) and mortality data from the Minnesota Center for Health Statistics confirm that AI/ANs in Minnesota suffer a disproportionate burden of cancer.
Over the 5-year period 1996-2000, the overall cancer incidence rate among AI/ANs in Minnesota was 66% higher and cancer mortality was 88% higher than among AI/ANs represented in national data (Figure 1 ). The risk of developing and dying from lung cancer in Minnesota AI/ANs was more than 2 times higher compared to national data (Table 1 ). Likewise, colorectal cancer incidence and mortality rates among AI/ANs in Minnesota were twice as high as among AI/ANs represented in national data. The incidence rate of breast cancer among AI/AN women in Minnesota was 14% lower than among AI/AN women represented in national data, but their mortality rate was 62% higher. Prostate cancer incidence and mortality rates among AI/AN men in Minnesota were 2 times higher than among AI/AN men represented in national data. National cancer incidence rates for AI/ ANs are based on data from the 12 geographic regions of the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program, which represents about 21% of AI/ANs in the United States; however, 75% of AI/ANs in the 
Review, 1975-2000
SEER 12 regions come from New Mexico, California, and Alaska. As a result, SEER incidence rates for the AI/ AN population are strongly influenced by the cancer rates among these 3 states and may present a biased picture of the cancer burden among AI/ANs nationwide. Since a national cancer registry does not exist, inci dence rates for this population in the United States as a whole are not available.
The reasons for these disparities in cancer among AI/ANs are not well understood. The higher rates of cancer among AI/ANs in Minnesota compared to national data for AI/ANs may be associated in part with the elevated prevalence of smoking in this popula tion. AI/ANs report the highest preva lence of current smoking among the major racial and ethnic groups in the United States
6
; however, cigarette smoking among AI/ANs is highest among Northern Plains Indians and lowest among those living in the Southwest.
7 Data for Minnesota are consistent with the national picture of cigarette smoking. Based on data from the Minnesota Behavioral Risk Factor Surveillance System for 1996-2000, American Indians were more than twice as likely as other racial and ethnic groups to report that they currently smoke.
Complete and accurate assessment of racial and ethnic differences in cancer risk in Minnesota is limited by several factors, including unknown accuracy of population estimates, incomplete or inaccurate reporting of race and ethnicity on medical records and death certificates, and the relatively small size of populations of color. The MCSS is working to address the issue of race misclassification on medical records by performing linkages of tumor registry data with data from the Indian Health Service. Such linkages will likely result in an increase in cancer rates for AI/ ANs in Minnesota as cancer patients whose race/ethnicity previously was unknown or misreported are identified as American Indians.
Health disparities in underserved and minority populations are of critical concern for medical and public health professionals. Cancer Plan Minnesota, a statewide initiative to develop a comprehensive cancer control plan, is making strides to further understand and address these issues. Cancer continued... 
Neisseria gonorrhoeae

Neisseria meningitidis
Group B Streptococcus (GBS)
Streptococcus pneumoniae
Antimicrobial treatment for enteric salmonellosis generally is not recommended.
Ciprofloxacin susceptibility was determined for all isolates (n=818). Only 37% of isolates from patients returning from foreign travel were susceptible to quinolones. Susceptibilities were determined using 2003 NCCLS breakpoints for Enterobacteriaceae. Susceptibility for erythromycin 4 µg/ml.
The 145 isolates tested comprised approximately 5% of total gonorrhea cases reported in 2003. All isolates were also susceptible to spectinomycin and 97% were susceptible to azithromycin. Five isolates (3%) had "decreased susceptibility" to azithromycin using provisional breakpoints 30 mm). Among 218 isolates tested through another surveillance system (GISP), 5 isolates were resistant to ciprofloxacin. 0.06 µg/ml considered susceptible, MIC of 0.12 -0.5 µg/ml considered "less susceptible" for penicillin. In 2003, 1 isolate had an MIC of 0.12 and 1 had an MIC of 0.25 µg/ml for penicillin.
All (20/20) early-onset infant, 94% (15/16) of late-onset infant, 75% (3/4) of maternal, and 87% (251/289) of invasive, non-infant, non-maternal GBS case isolates were tested. 84% (32/38) of infant and maternal case isolates were susceptible to clindamycin and 79% (30/38) were susceptible to erythromycin. 0.5 µg/ml to cefazolin.
The 567 isolates tested represented 93% of 607 total cases. 6% (32/567) had intermediate susceptibility and 8% (47/567) were resistant to penicillin. Reported above is the proportion of case isolates susceptible by meningitis breakpoints for cefotaxime (intermediate=1.0 µg/ml, resistant > 4.0 µg/ml) 99% (562/567) of isolates were susceptible. Isolates were screened for high-level resistance to 2 µg/ml. 12% (70/567) of isolates were resistant to two or more antibiotic classes and 8% (47/567) were resistant to 3 or more antibiotic classes.
continued... 
